Achievements in Russian Pediatric Rheumatology: Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences

25.11.2024 состоялось очередное заседание Совета по терапевтическим наукам Секции клинической медицины РАН, которое было посвящено достижениям детской ревматологии в России. Целью данного Заседания стало обсуждение актуальных вопросов педиатрической ревматологической практики. 

1. Rosina S, Rebollo-Giménez AI, Consolaro A, et al. Treat-to-Target in Pediatric Rheumatic Diseases. Curr Rheumatol Rep. 2023;25(11):226-35. doi:10.1007/s11926-023-01112-x.

2. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30(9): 1163-72. doi:10.1007/s10067-011-1720-7.

3. Alexeeva EI, Dvoryakovskaya TM, Isaeva KB, et al. Early Predictors of the Response to Adalimumab Therapy in Patients with Juvenile Idiopathic Arthritis without Systemic Manifestations: A Prospective Cohort Study. Current Pediatrics. 2018;17(5):381-8. (In Russ.) doi:10.15690/vsp.v17i5.1954.

4. Alexeeva EI, Dvoryakovskaya TM, Isaeva KB, et al. Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study. Current Pediatrics. 2019;18(1):31-40. (In Russ.) doi:10.15690/vsp.v18i1.1989.

5. Krekhova EA, Alexeeva EI, Dvoryakovskaya TM, et al. Predictors of Remission in Children with Systemic Juvenile Idiopathic Arth­ritis Receiving Biologicals (Tocilizumab and Canakinumab): A Co­hort Study. Clinical practice in pediatrics. 2022;17(1):95-112. (In Russ.) doi:10.20953/1817-7646-2022-7-95-112.

6. Nigrovic PA, Raychaudhuri S, Thompson SD. Genetics and the Classification of Arthritis in Adults and Children. Arthritis Rheumatol. 2018;70(1):7-17. doi:10.1002/art.40350.

7. Nikishina IP, Kostereva OM. Juvenile arthritis in pediatric and adult rheumatology service: the problem of continuity in the management of patients. Scientific and Practical Rheumatology. 2018; 56(2):138-43. (In Russ.) doi:10.14412/1995-4484-2018-138-143.

8. Nasonov EL, Lila AM, Kriulina TYu, et al. Problems of providing me­dical care to the population in the profile of rheumatology: results of the all-Russian survey. Clinical practice in pediatrics. 2024;19(3):8-22. (In Russ.) doi:10.20953/1817-7646-2024-3-8-22.

9. Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arth­ritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819-828. doi:10.1136/annrheumdis-2018-213030.

10. Kolkhidova ZA, Nikishina IP, Glukhova SI. Assessment of the da­ma­ge index and its dynamics in patients with non-systemic va­riants of juvenile arthritis during the treatment with biologics. Rheumatology Science and Practice. 2024;62(3):309-18. (In Russ.) doi:10.47360/1995-4484-2024-309-318.

11. Van der Heijde D, Daikh DI, Betteridge N, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers, and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Arthritis Rheumatol. 2018;70:826-31. doi:10.1002/art.40448.

12. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300. doi:10.1002/art.10529.

13. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. doi:10.1093/ofid/ofu024.

14. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023;75(3):449-64. doi:10.1002/acr.25045.

15. Hashkes PJ, Laxer RM, Simon A. Textbook of autoinflammation. Springer, 2019. р.820. ISBN: 978-3-319-98604-3, ISBN: 978-3-319-98605-0 (eBook). doi:10.1007/978-3-319-98605-0.

16. Fedorov ES, Salugina SO, Kuzmina NN. Development of the doctrine of auto-inflammatory diseases in the XXI century. Rheumatology Science and Practice. 2018;56:5-18. (In Russ.) doi:10.14412/1995-4484-2018-5-18.

17. Salugina SO, Fedorov ES, Agafonova EM. Monogenic auto-in­flammatory diseases in children and adults: what a rheumatologist should know. Rheumatology Science and Practice. 2019;57(2):125-32. (In Russ.) doi:10.14412/1995-4484-2019-125-132.

18. Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78(8): 1025-32. doi:10.1136/annrheumdis-2019-215048.

19. Ter Haar N, Oswald M, Jeyaratnam J, et al. Recommendation for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636-44. doi:10.1136/annrheumdis-2015-207546.

20. Federici S, Martini A, Gattorno M. The Central Role of Anti-IL-1 Blo­ckade in the Treatment of Monogenic and Multi-Factorial Auto­inflammatory Diseases. Front Immunol. 2013;4:351. doi:10.3389/fimmu.2013.00351.

21. Salugina SO, Fedorov ES, Kaleda MI. Biological disease-modifying antirheumatic drugs in the main monogenic autoinflammatory diseases treatment. Experience of application in rheumatological practice. Sovremennaya Revmatologiya=Modern Rheumatology Jour­nal. 2021;15(4):24-30. (In Russ.) doi:10.14412/1996-7012-2021-4-24-30.

22. Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. doi: 10.1134/S1019331622040062.

23. Kokina MYu, Fomina DS, Isaeva KB, et al. Features of Clinical and Laboratory Manifestations of Secondary Hemophagocytic Syndrome in Children with Rheumatic Diseases Developed after a New Coronavirus Infection (COVID-19). Clinical practice in pe­diatrics. 2024;19(4):7-16. (In Russ.) doi:10.20953/1817-7646-2024-4-7-16.

24. Alexeeva EI, Kokina MYu, Fomina DS, et al. Assessment of the safety of the two-component drug of monoclonal antibodies to SARS-CoV-2 (tixagevimab cilgavimab) for pre-exposure prophylaxis of the new coronavirus infection in children with rheumatic diseases. Pediatria n.a. G. N. Speransky. 2024;103(5):8-28. (In Russ.) doi:10.24110/0031-403X-2024-103-5-8-28.

25. Tarvin SE, O’Neil KM. Systemic Lupus Erythematosus, Sjögren Syn­drome, and Mixed Connective Tissue Disease in Children and Adolescents, Pediatric Clinics of North America. 2018;65(4):711-37. doi:10.1016/j.pcl.2018.04.001.

26. Kaleda MI, Nikishina IP. Problems of systemic connective tissue di­seases of childhood in historical perspective. Rheumatology Science and Practice. 2023;61(6):639-49. (In Russ.) doi:10.47360/1995-4484-2023-639-649.

27. Kobayashi I. Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review. Children (Basel). 2024;11(9):1046. doi:10.3390/children11091046.

28. Osminina MK, Geppe NA. Classification, Clinical Picture, and Therapy of Juvenile Scleroderma. Rheumatology Science and Practice. 2015;53(2):214-9. (In Russ.) doi:10.14412/1995-4484-2015-214-219.

29. Kaleda MI, Nikishina IP. Modern treatment options for systemic lupus erythematosus in children (literature review). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2024;18(4):99-105. (In Russ.) doi:10.14412/1996-7012-2024-4-99-105.

30. Crayne CB, Albeituni S, Nichols KE, et al. The Immunology of Mac­ro­phage Activation Syndrome. Front Immunol. 2019;10:119. doi:10.3389/fimmu.2019.00119.

31. Henderson LA, Cron RQ. Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management. Paediatr Drugs. 2020;22(1):29-44. doi:10.1007/s40272-019-00367-1.

32. Kriulin IA, Alexeeva EI, Shilkrot IYu, et al. Treatment of Secondary Hemophagocytic Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis. Results of a Cohort Retrospective Study. Clinical practice in pediatrics. 2022;17(5):7-19. (In Russ.) doi:10.20953/1817-7646-2022-5-7-19.